Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors have established roles in selected advanced and postoperative esophageal squamous cell carcinoma settings, but evidence supporting an immunotherapy-containing regimen does not necessarily establish its optimal initiation time. This narrative review evaluates timing within advanced, neoadjuvant, postoperative, and definitive chemoradiotherapy pathways. A targeted synthesis of the previously assembled literature through August 2026 was supplemented by separately documented citation and protocol checks; incomplete historical search documentation limits reproducibility. Evidence is classified by study design and whether initiation timing was actually randomized. Phase III trials support first-line chemoimmunotherapy in appropriate advanced-disease populations, whereas the randomized neoadjuvant HCHTOG1906 trial did not demonstrate superior pathological response or survival with cycle-day-3 versus same-day toripalimab. CRISEC and EPOC1802 used post-chemoradiotherapy schedules without randomizing start time. Biological observations and prolonged antibody activity do not identify a transferable calendar window. We propose a research framework that distinguishes established safety requirements, protocol-specific eligibility thresholds, and unvalidated recovery measurements; operationalizes subsequent-treatment completability through prespecified pathway milestones; and separates prognostic, predictive, pharmacodynamic, and safety/readiness biomarkers. Future trials should specify the population, treatment strategies, common time zero, intercurrent-event handling, and primary estimand. Failure to reach assigned treatment must remain visible in intention-to-treat analyses, while survival, disease control, treatment delivery, and patient-reported recovery require setting-specific prioritization. Established stage-specific treatment should remain the clinical reference rather than be displaced by an unvalidated timing strategy.
No takes yet. Share an insight, caveat, or question.
Ning et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: